Vamshi Rao, MD, attending physician of Neurology at Ann and Robert H. Lurie Children’s Hospital of Chicago discusses how the pandemic has impacted access to spinal muscular atrophy (SMA) treatments.
Vamshi Rao, MD, is an attending physician of Neurology at Ann and Robert H. Lurie Children’s Hospital of Chicago and assistant professor of Pediatrics (Neurology and Epilepsy) at Northwestern University Feinberg School of Medicine.
Transcript:
Has the COVID-19 [coronavirus disease 2019] pandemic impacted access to either newborn screening for spinal muscular atrophy [SMA] type 1 or to treatments?
Rao: We've been very fortunate that COVID-19 overall has not impacted the access to treatments and newborn screening. I can speak for the state of Illinois because that is where I practice. Newborn screening was introduced as a pilot somewhere between May and July 2020 and rapidly took over as a permanent program after that. All of the children that are being born in the state of Illinois are definitely going through newborn screening and COVID-19 has not affected that. As far as access to treatment, access to treatment at a particular institution for a therapy that requires children to come to the hospital, such as Spinraza [nusinersen] that is given through lumbar puncture, or on a *17 hour power glycosyltransferase* that is given through IV [intravenous injection] requires children to come to the hospital.
Guidelines that required COVID-19 precautions were in place in most people places, and guidelines have to be practiced. But at the same time, a very risk-benefit analysis was done in terms of exposure vs children getting treatment and I'm happy to say that, at least at our institution, as we really looked at these guidelines [with] a committee that was formed to assess whether children were going to come in for their regular treatments, and clinical trials, it was found that the risk of not getting the medication vs the risk of getting COVID was definitely in favor of decline with the underlying estimate if they did not get their medication. So all these children were allowed to have their disease modifying therapies given to them at our hospital.
I definitely think that access was affected at some institutions and I do think access was affected around the country, in places where a lot of travel was involved in whether kids were coming from rural communities, or coming from very far off, mountainous regions to their nearest center that was giving them these drugs. Overall, I do think there were places that where access was affected, but as an SMA community, our goal was to always administer the drug despite all odds, of course, keeping all the safety and precautions in place.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More